BIAF - bioAffinity Technologies Enterprise Value

bioAffinity Technologies (BIAF) develops non-invasive methods for the early detection of lung tumors via sputum analysis, while expanding its screening portfolio across various cancer types minimizes financial losses, although the probability of clinical trial failure and medical insurance complexities create certain barriers. The price action, which currently stands at 2.64, is illustrated below. Efficient express delivery of diagnostic kits to laboratories ensures a stable supply for clinics.

For bioAffinity Technologies (BIAF), the developer of CyPath Lung whose tests generate a steady cash flow through insurance programs, the enterprise value trajectory on GURU.Markets reflects the actual business acquisition cost. This indicator aggregates market capitalization and net debt, allowing investors to assess the total buyout price of the asset inclusive of cash, thereby eliminating the distortions of standard equity valuations between quarterly reports.